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Two multicentre genome-wide association (GWA) studies provided substantial evidence,
implicating the complement receptor 1 gene (CR1) in Alzheimer disease (AD) genetic etiology.
CR1 encodes a large transmembrane receptor with a crucial role in the immune complement
cascade. We performed a genetic follow-up of the GWA CR1 association in a Flanders–Belgian
cohort (n=1883), and investigated the effect of single-nucleotide polymorphisms (SNPs)
located in the CR1 locus on AD risk and cerebrospinal fluid (CSF) biomarker levels. We
obtained significant association (Padj<0.03; odds ratio (OR)=1.24 (95% confidence interval
(CI): 1.02–1.51)) for one CR1 risk haplotype, and haplotype association was strongest
in individuals carrying apolipoprotein E (APOE) e4 alleles (Padj<0.006; OR=1.50 (95% CI:
1.08–2.09)). Also, four SNPs correlated with increased CSF amyloid Ab1 42 levels, suggesting a
role for the CR1 protein in Ab metabolism. Moreover, we quantified a low-copy repeat (LCR)-
associated copy number variation (CNV) in CR1, producing different CR1 isoforms, CR1-F and
CR1-S, and obtained significant association in carriers of CR1-S. We replicated the CR1 CNV
association finding in a French cohort (n=2003) and calculated in the combined cohorts,
an OR of 1.32; 95% CI: 1.10–1.59 (P=0.0025). Our data showed that the common AD risk
association may well be explained by the presence of CR1-S increasing the number of C3b/C4b
and cofactor activity sites and AD risk with 30% in CR1-S carriers. How precisely the different
functional role of CR1-S in the immune complement cascade contributes to AD pathogenesis
will need additional functional studies.
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Introduction
Two independent multicentre genome-wide associa-
tion (GWA) studies, comprising over 25000 individ-
uals,
1,2 provided genome-wide significant evidence
for Alzheimer disease (AD, MIM#104300) risk asso-
ciation of three novel genes, besides the apolipo-
protein E gene (APOE). Apart from the clusterin gene
(CLU, MIM*185430), which was identified in both
the GWA cohorts, the Cardiff GWA study identified
the phosphatidylinositol-binding clathrin assembly
protein gene (PICALM, MIM*603025) and the French
GWA study the complement receptor 1 (CR1,
MIM*120620).
1,2 In CR1, the single-nucleotide poly-
morphism (SNP) rs6656401 showed the strongest
association with an odds ratio (OR) of 1.19 (95%
confidence interval (CI):1.12–1.28) and a P-value of
9.8 10
 8.
2 Further, AD risk association showed
interaction with APOE genotype and was strongest
in APOE e4 carriers (OR=1.36 (95% CI: 1.20–1.53)).
2
A second SNP, rs3818361, showed evidence for
association only in the APOE e4 stratum (OR=1.34
(95% CI: 1.19–1.51), P=1.5 10
 6).
CR1, also known as CD35, immune adherence
receptor or complement component (3b/4b) receptor
1, is a large type-I transmembrane glycoprotein. It
is an important member of the family of regulators
of complement activation and a crucial, multifunc-
tional mediator of innate immunity. Its wide range of
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www.nature.com/mpfunctions can predominantly be perceived as the
result of its capacity to bind complement components
C3b and C4b. CR1 functions as a major immune
adherence molecule on erythrocytes, transporting
complement-opsonized particles to liver and spleen
for clearance from the blood. In other cells, CR1
binding to complement components induces phago-
cytosis of the opsonized complexes. Lastly, CR1
functions as an inhibitor of the complement cascade
by exerting decay accelerating activity toward the
C3/C5 convertases and/or cofactor activity for factor
I-mediated cleavage of C3b/C4b.
3,4
Different CR1 isoforms have been identified, vary-
ing in size by units of B30kDa.
3,5,6 The most common
isoform, designated CR1-F (also CR1-A or CR1*1),
has a frequency of 83%, and a molecular weight of
220kDa, whereas the second most common isoform,
CR1-S (CR1-B or CR1*2) has a frequency of 15% and a
molecular weight of 250kDa (Figure 1). In addition,
two rare isoforms have also been described of 190kDa
(CR1-F0, CR1-C or CR1*3; frequency 1%) and 280kDa
(CR1-D or CR1*4; frequency <1%).
3 The CR1 extra-
cellular domain is entirely composed of tandem
repeated units of a conserved domain of 60–70 amino
acids, known as short consensus repeat (or comple-
ment control repeat or sushi domain).
3 All short
consensus repeats, except the last two, are organized
into higher order repeat units composed of seven
short consensus repeats, termed long homologous
repeats (LHRs)
3,7 (Figure 1). Of the four LHRs (LHR-A
to -D; Figure 1), all but LHR-D bind C3b and/or
C4b, resulting in inhibition of complement acti-
vation through decay accelerating activity or cofactor
activity.
8,9 CR1 is located at chromosome 1q32 in a
regulators of complement activation gene cluster,
3
and encompasses a variable number of 18-kb
long low-copy repeats (LCRs)—LCR1 and LCR2
10,11
(Figure 1). Both LCR1 and LCR2 are located in the
CR1-coding region, and so is LCR10, the extra LCR1-
derived copy. The presence of LCR10 explains the
extra LHR, LHR-S in the long CR1-S isoform, creating
additional C3b/C4b binding sites. The rare isoforms
CR1-D and CR1-F0 result from either a triplication
or deletion of one LCR1 copy. The third LCR, LCR3,
is located in the neighboring CR1-like gene, CR1L.
Because of the myriad of functions ascribed to CR1,
the protein and its potential role in disease has been
intensively studied.
4 Although biological evidence
for a direct role of CR1 in AD etiology is lacking, CR1
might be involved at several levels. For instance,
it has long been established that neuroinflammation
and, more specifically, activation of the comple-
ment system, has an important role in pathological
processes in AD brains.
12–14 CR1 might be involved
in amyloid b (Ab) clearance from brain as fibrillar
Ab peptides were shown to activate the complement
cascade and become covalently bound to C3b,
15–17
and CR1 induces clearance and/or phagocytosis
of C3b-opsonized particles. Interestingly, it has been
demonstrated that in plasma, C3b mediates adherence
of Ab peptides to erythrocyte CR1, a process impaired
early in the course of AD.
18 Thus, CR1 may well
contribute to AD by altering clearance of Ab in the
periphery (in line with the peripheral sink hypothesis
stating that Ab can be cleared from the brain by Ab-
binding molecules in the periphery). On the other
hand, as CR1 is a potent regulator of the complement
system, it could also participate in the disease process
by inhibiting complement activation in brain, which
in some studies of AD animal models had a
detrimental rather than a beneficial effect.
19,20
In light of these findings, we initiated an in-depth
follow-up of the GWA association finding in a
Flanders–Belgian cohort of well-characterized AD
patients and control individuals (n=1883). Part of this
cohort had been included as replication sample in the
French GWA study and showing a trend towards
association with rs6656401 of OR=1.24 (95% CI:
0.99–1.24; P=5.6 10
 2, n=1566) and rs3818361 of
OR=1.05 (95% CI: 0.84–1.48; P=6.8 10
 1, n=1408).
2
Here, we examined in detail this risk association using
multiple SNPs based on linkage disequilibrium (LD)
and genetic variability within the CR1 locus. Also, we
analyzed a potential correlation between CR1 SNPs and
AD cerebrospinal fluid (CSF) biomarkers. Further, we
quantified the CR1 LCRs by defining the different-sized
C R 1i s o f o r m sSa n dFt ot e s tw h e t h e rA Dr i s km a yb e
attributed to a specific CR1 isoform. To further
strengthen our observations, we analyzed our genetic
findings obtained in the Flanders–Belgian cohort in an
independent French cohort.
Materials and methods
Study cohorts
All studies were approved by the medical ethics
committees of the Hospital Network Antwerp (ZNA),
University of Antwerp, the University Hospitals
Leuven, Lille University Medical Center and
Universite ´ de Lille. After written informed consent,
blood samples were obtained for genomic DNA
extraction, generation of EBV cell lines and plasma
and serum collection.
The Flanders–Belgian AD group consisted of 1039
patients (mean onset age 74.1±9.1 years, 65.4%
women) ascertained at the memory clinics of the
ZNA Middelheim, Antwerpen, Belgium
21,22 and the
University Hospitals Leuven, Leuven, Belgium,
23
as previously described.
23 Consensus diagnosis of
possible or probable AD was given by at least two
neurologists, based on the NINCDS/ADRDA criteria.
24
The Flanders–Belgian control group consisted of
844 healthy, unrelated individuals from Belgium
(mean age at inclusion 65.4±14.8 years, 57.0%
women).
23 The French cohort consisted of Caucasian
individuals ascertained in the north of France,
25,26
and represents part of the study population used in
the French GWAS.
2 French AD patients (n=1393,
mean onset age 69.5±8.0 years, 66.1% women) were
diagnosed as probable AD according to the DSM-III-R
and NINCDS/ADRDA criteria.
24 The French control
group consisted of n=610 healthy individuals (mean
CR1-S isoform associated with AD risk
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Supplementary Methods for a detailed description of
the study cohorts.
Biomarker profiling
Cerebrospinal fluid levels of b-amyloid protein1 42
(Ab1 42), total tau (T-tau) and tau phosphorylated at
threonine 181 (P-tau181P) were determined blinded and
in duplicate, with commercially available single-param-
eter ELISA kits (Innogenetics, Gent, Belgium), following
the instructions provided by the manufacturer (for
details see Supplementary Methods). Biomarker profiles
were available for 339 Flanders–Belgian AD patients
(mean onset age 75.8±8.5 years, 63.2% women).
Figure 1 Genomic architecture of the CR1 locus in relation to the major CR1 isoforms. The upper triangle shows a dot plot of
the self-alignment of the genomic region (50 to 30) encompassing the genes CR1 and CR1-like (CR1L). Dot plot colors represent
sequence identity. Low-copy repeats (LCRs) are represented as horizontal arrows below the dot plot. The genomic segment is
graphically annotated at different levels below the dot plot. Annotation is given for the two major CR1 isoforms CR1-S and
CR1-F. LCRs: arrows indicate location and orientation of the LCRs. The LCR present at variable number of copies, resulting in
the CR1 isoforms indicated with pink arrows. Multiplex amplicon quantification (MAQ) ampl: location of amplicons 1–4,
used for the CR1 LCR dosage analysis. Gene: location and exon structure of CR1 and CR1L. Transcript: organization of the
CR1 transcripts. Boxes represent exons with wide regions representing coding sequences and narrow regions untranslated
sequences (UTRs). Arrows show the organization of the long homologous repeat regions (LHRs). The open box labeled TM
denotes the region encoding the transmembrane domain. Protein: CR1 functional domains with each circle representing a
separate short consensus repeat. The first three short consensus repeats in LHR A, S, B and C are required for complement
factor binding and inhibitory activity (decay accelerating activity or cofactor activity), in which the first two determine factor-
binding specificity and the type of inhibition, indicated by different hatching patterns.
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TagSNPs (n=26) throughout the CR1 locus were
selected for association analyses from the Interna-
tional HapMap Project (Rel24/phaseII
27) using Haplo-
View v4.2.
28 Details regarding the SNP selection
criteria are described in the Supplementary Methods
section. SNP genotyping was performed in two
multiplex assays by MassARRAY using iPLEX Gold
chemistry (Sequenom, Hamburg, Germany), followed
by MALDI-TOF mass spectrometry. PCR and exten-
sion primers were designed using MassARRAY Assay
Design software v3.0.2.0 (Sequenom). Genotypes were
called automatically using MassARRAY Typer soft-
ware v4.0 (Sequenom) and were visually inspected by
two researchers blinded for disease status. Samples
that failed for >20% of the genotyping assays were
disregarded for further analysis (n=35). The APOE
genotype assay and data were previously described.
29
Dosage analyses
Copy number status of the 18-kb long LCRs in CR1
and CR1L (Figure 1) was determined using multiplex
amplicon quantification (MAQ) (Multiplicon SA,
http://www.multiplicon.com), as described.
30 Briefly,
three fluorescently labeled test amplicons, targeting
specifically LRCs 1–3 (Figure 1), and seven control
amplicons, recognizing sequences outside the CR1
locus, were amplified in one multiplex PCR reaction
and resolved on an Applied Biosystems 3730xl DNA
analyzer (Applied Biosystems, Foster City, CA, USA).
Peak areas of the test amplicons were normalized
based on the peak areas of the control amplicons.
From these normalized peak areas dosage quotients
were calculated by dividing the ratios from the test
individuals by that of reference individuals. Ampli-
con 1, designed to target LCR1, also recognizes LCR10
because of their very high-sequence homology. Pre-
sence or absence of LCR10 determines CR1-S (250kDa)
and CR1-F (220kDa). Dosage analysis was performed
using MAQ-S software (Multiplicon SA, Antwerpen,
Belgium).
Western blotting
Cultured lymphoblast cells of patients and control
individuals were lysed using NP-40 lysis buffer
(50mM Tris-HCl, 150mM NaCl, 1% Nonidet P-40)
supplemented with protease inhibitors (Complete
protease inhibitor cocktail, Roche (Vilvoorde,
Belgium)). Protein concentration was measured using
the bicinchoninic acid method (Pierce BCA Protein
Assay, Thermo Scientific, Erembodegem, Belgium)
and 30mg were used for electrophoresis. Protein
samples were separated on a 3–8% Tris-acetate
NuPage gel (Invitrogen, Merelbeke, Belgium) under
reducing conditions. Resolved proteins were electro-
blotted onto a polyvinylidene difluoride membrane
(Amersham Hybond-P PVDF Membrane, GE Health-
care, Diegem, Belgium). After blocking, membranes
were immunoblotted with CD-35 (H-2) mouse mono-
clonal antibody (1:100, Santa Cruz Biotechnology,
Heidelberg, Germany, sc-166329). Immunodetection
was performed with a Horseradish peroxidase-coupled
sheep anti-mouse secondary antibody (1:10000,
GE Healthcare) and Amersham ECL Plus Western
Blotting Detection Reagents (GE Healthcare).
Statistical analyses
SNP associations. Deviations from Hardy–Weinberg
equilibrium of genotype frequencies were deter-
mined using an exact Hardy–Weinberg equilibrium
test (http://www.pharmgat.org/IIPGA2/Bioinformatics/
exacthweform). Allele and genotype frequencies
between AD patients and control individuals were
compared using w
2-statistics in SPSS 16.0 (SPSS Inc.,
Chicago, IL, USA). Odds ratio (relative to the common
genotype) and 95% CI were calculated, adjusted for
onset/inclusion age, gender and APOE e4 genotype
(absence/presence of e4 allele), using binary logistic
regression analysis. LD between the 26 tagSNPs was
calculated using Haploview v4.2, and LD blocks (n=5)
were based on the solid spine of LD rule (Haploview,
Supplementary Table S1). An LD plot with r
2 as the LD
measure was drawn using the LDheatmap v0.2.8
package.
31 Haplotype analyses were performed with
Haplo Stats v1.4.4
32 by means of haplotype tagging
SNP, selected with Haploview v4.2. Using progressive
insertion EM algorithms, haplotype frequencies were
estimated and compared between patients and control
individuals using score statistics (estimated frequency
>0.01). Analyses were adjusted for onset/inclusion age,
gender and APOE e4 genotype. For significantly
associated haplotypes, ORs and corresponding 95%
CIs (corrected for age, gender and APOE e4 genotype)
were calculated in Haplo Stats v1.4.4. To avoid false-
positive results due to multiple testing, we computed
simulated P-values (1000 random permutations of
patient and control labels).
Effect of SNP genotypes on biomarker profiles of
patients was assessed using univariate analysis
of variance analyses, adjusted for age and disease
duration at lumbar puncture and gender, using SPSS.
To assess the effect on CSF Ab1 42 levels, APOE e4
genotype was included as a covariate in the model,
as this correlated significantly with Ab1 42 levels.
T-tau and P-tau181P levels were log10 transformed to
approximate normality before analysis of variance.
Copy number variation associations. Association
analyses of the CR1 LCR1 with disease status were
performed using CNVassoc,
33 and normalized signal
intensities or dosage quotients obtained from MAQ
analysis. Association analyses were performed
through logistic regression (adjusted for age, gender
and APOE e4 genotype) taking into account copy
number variation (CNV) calling uncertainty in a latent
class model. To assess the effect of the different CNV
classes we used a multiplicative model.
Conditional logistic regression was used to assess
independence of the SNP and CNV associations. LD
between the LCR1 CNV and the 26 tagSNPs in the
CR1 locus was estimated by recoding CNV status
CR1-S isoform associated with AD risk
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three copies=A/B, four copies=B/B; introducing
a slight bias as the allelic status of individuals with
four copies cannot unambiguously be determined)
and estimating LD (Haploview).
Meta-analyses. Pooled OR for rs4844610 and the
LCR1 CNV in the Flanders–Belgian and French
cohorts were calculated by random-effects meta-
analysis (Der Simonian-Laird), based on the effect
estimates obtained in the individual cohorts (adjusted
for age, gender and APOE e4 genotype). Analyses
were performed and forest plots generated using the
package rmeta in R (http://cran.r-project.org/web/
packages/rmeta/index.html).
Results
CR1 SNP association in Flanders–Belgian cohort
We genotyped 26 tagSNPs located across the CR1
locus. The selected SNPs had a minor allele frequency
(MAF)>5%, were located outside the CR1 LCRs or
other repeat sequences, were in Hardy–Weinberg
equilibrium in the control group and captured 87%
of the genetic variability within the locus (Supple-
mentary Table S1). SNPs rs4844610 and rs1408077
showed significant allelic association with AD risk
(Padj<0.03) (Figure 2, Supplementary Table S2). LD
was very high between the two associated SNPs
(r
2=0.97), as well as between the two associated SNPs
in our study and the two SNPs rs6656401 and
rs3818361 (0.87<r
2<0.90), that were associated with
AD in the French GWA study.
2 Our SNP selection
criteria did not include the two French GWA SNPs as
they are located in CR1 LCRs or repeat sequences.
Stratification for APOE e4 genotype indicated that the
AD risk association was predominantly observed in
APOE e4 carriers (allelic association Padj<0.01)
(Figure 2, Supplementary Table S2).
On the basis of LD structure in the CR1 locus, the 26
tagSNPs could be assigned to five LD blocks (Supple-
mentary Table S1, Figure 2). Haplotype association
analyses using haplotype tagging SNPs per LD block
showed significant association only in LD block 4.
This block 4 is located between the two recombina-
tion hotspots and spans nearly the entire gene CR1,
except for the first and last exons (130kb, Supple-
mentary Table S3, Figure 2). The association resulted
from the overrepresentation in patients of one
haplotype (HapB; ORHapB=1.24, 95% CI: 1.02–1.51;
Padj=0.027). This risk haplotype harbored the risk
allele of both the associated SNPs rs4844610 (A-
allele) and rs1408077 (A-allele). In accordance with
the single SNP analyses, haplotype association was
also more evident in APOE e4 carriers (ORHapB=1.50,
95% CI: 1.08–2.09; Padj=0.006).
CR1 SNP correlation with CSF biomarkers
We assessed the effect of CR1 SNPs on AD biomarkers,
considering CSF levels of Ab1 42, T-tau or P-tau181P in
AD patients as a quantitative trait. There was no
evidence for an effect of rs4844610 or rs1408077 on
CSF Ab1 42, T-tau or P-tau181P levels. In contrast, we
observed overall significant increased Ab1 42 levels for
carriers of the minor allele at four SNPs in LD block 4
(Supplementary Table S4, Figure 3), that is, rs646817,
rs1746659, rs11803956 and rs12034383, of which
the former two and the latter two represent the same
signals because of high pairwise LD (r
2X0.99). As the
number of homozygous carriers of the minor allele
was small for rs646817 (and, given the high r
2,f o r
rs1746659 (n=18)), we also calculated the effect of
this SNP on Ab1 42 levels under a dominant genotype
model, showing further evidence for association
(Poverall=0.018). Haplotype analysis in LD block 4
showed HapC (Padj=0.016) and HapD (Padj<0.001) to
be significantly associated with increased levels of CSF
Ab1 42. Both haplotypes contain the associated alleles
of the four SNPs (Supplementary Table S3).
CR1 CNV association in Flanders–Belgian cohort
To determine whether a specific protein CR1 isoform
could be associated with risk for AD, we determined
copy number status of the three LCRs (LCR1, LCR2
and LCR3) located in the CR1 locus using a MAQ
assay. We designed three test amplicons, 1 to 3,
specifically targeting these LCRs (Figure 1). Test
amplicon 1 also recognizes LCR10, whereas LCR2 is
targeted by amplicon 2 and LCR3 by amplicon 3.
Quantitative dosage analysis of the target ampli-
cons versus control amplicons showed that nearly
all variations resulted from test amplicon 1. Copy
numbers varied between 2 and 4 for individuals
homozygous LCR1/LCR1, heterozygous LCR1/LCR1,
LCR10 and homozygous LCR1, LCR10/LCR1and LCR10
(Table 1). To confirm that the copy numbers of the
CR1, LCR1 CNV correlated with the predicted protein
isoforms F (one copy of LCR1) and S (two copies,
LCR1 and LCR10), we performed CR1 immunoblotting
of lymphoblast cell lysates (Figure 4). In majority
of the individuals, the LCR1 CNV copy number
corresponded with the predicted lengths of CR1-F
(220kDa, one LCR1 copy) and CR1-S (250kDa, two
LCR1 copies). Also, the genotype frequencies of the
LCR1 CNV were in agreement with previously
reported frequencies of CR1-F (83%) and CR1-S
(15%) (Table 1). However, in three out of eight tested
individuals carrying four copies of the LCR1 CNV
(37.5%), western blotting detected a 280kDa band
corresponding to CR1-D and resulting from a triplica-
tion of LCR1 on one allele, together with the 220kDa
CR1-F. As there were 84 individuals carrying four
LCR1 copies, the number of individuals with F/D
genotype may well be 32, that is, 1.8% of the
total cohort of 1717 individuals. This is in line with
the predicted frequency (B1.7%) based on the
reported frequencies of CR1-F (83%) and CR1-D
(<1%). Further, in 3.5% of the individuals (n=60),
amplicon 2 dosage variation instead of amplicon 1
was observed (Figure 4). Here, copy number varied
between 3 (heterozygous for CR1-S, 1.7%) and 1
(heterozygous for CR1-F0, 1.8%), of which the latter
CR1-S isoform associated with AD risk
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frequency (1.66%). No dosage variation was observed
for LCR3 in CR1L.
To assess whether the common LCR1 CNV contri-
butes to AD risk, we performed an association ana-
lysis with disease status. Individuals carrying three
Figure 2 LD structure of the CR1 locus and single single-nucleotide polymorphism (SNP) allelic association in AD. Allelic
associations corrected for age (onset/inclusion), gender and APOE e4 genotype (for analyses not stratified for APOE e4
genotype) are plotted as  log10(P). SNPs are placed in the graph according to their position in CR1 shown below the graph.
The lower panel of the figure shows the pairwise linkage disequilibrium pattern between SNPs as measured by their
r
2 values.
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compared with carriers of two copies (Padj=0.028;
Table 1). The CNV was in LD with the two associated
SNPs, with an estimated r
2=0.78 and r
2=0.76
between CNV and rs4844610 and rs1408077, respec-
tively. Conditional logistic regression showed that the
associations of both the LCR1 CNVand the SNPs with
AD risk represented the same association signal.
Figure 3 Association of SNP genotypes with Ab1 42 cerebrospinal fluid (CSF) levels. CSF Ab1 42 levels (pgml
 1) measured
in patients carrying different single-nucleotide polymorphism (SNP) genotypes. Because of high r
2 values between rs646817
and rs1746659, and between rs12034383 and rs11803956, only results for rs646817 and rs12034383 are shown. Significant
pairwise comparisons are indicated, that is, AA vs AGþGG for rs646817 and AA vs GG for rs12034383, with P-values
corrected for age at lumbar puncture, disease duration at lumbar puncture, gender and APOE e4 genotype. For rs646817,
results of the association test under a dominant model are depicted.
Table 1 Association of AD with LCR1 CNV
LCR1 CNV CR1 isoform Patients Controls PP -adj OR 95% CI
n n % n %
Belgian sample
2 F/F 595 62.3 525 68.9 0.013 0.083 ref.
3 F/S 312 32.7 201 26.4 0.003 0.028 1.32 1.03–1.69
4 S/S or F/D 48 5.0 36 4.7 0.574 0.583 1.16 0.69–1.94
French sample
2 F/F 793 64.9 406 70.5 0.084 0.049 ref.
3 F/S 354 30.0 142 24.7 0.032 0.039 1.33 1.02–1.74
4 S/S or F/D 74 6.1 28 4.9 0.500 0.456 1.44 0.87–2.40
Abbreviations: AD, Alzheimer disease; CI, confidence interval; CNV, copy number variation; CR1, complement receptor 1
gene; LCR, low-copy repeats; OR, odds ratio.
Note: significant associations (P<0.05) are indicated in bold; P-adj represent P-values adjusted for age, gender and APOE e4
genotype.
CR1-S isoform associated with AD risk
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To replicate our association findings, we genotyped
SNP rs4844610 and LCR1 CNV in an independent
French cohort and calculated the association with AD
risk. Association with rs4844610 was nonsignificant
in the French cohort (ORCA vs CC=1.20, 95% CI:
0.95–1.52; Padj=0.134), but the meta-analysis in
the combined Flanders–Belgian and French cohorts
provided significant results with a summary ORCA vs
CC=1.31 (95% CI: 1.11–1.55; P=0.0015; heterogeneity
P-value=0.317) (Supplementary Figure S1). The
LCR1 CNV association results in the French cohort
were comparable to those obtained in the Flanders–
Belgian cohort with individuals carrying three copies
of the LCR1 CNV having a 30% increased risk for
AD (Table 1). Meta-analysis in the combined cohorts
further confirmed these observations with and OR
of 1.32 (95% CI: 1.1–1.59; P=0.0025; heterogeneity
P-value=0.975) (Supplementary Figure S1).
Discussion
In this study, we focused on examining the role of
CR1 in AD genetic risk in an extended Flanders–
Belgian cohort by assessing single-nucleotide varia-
tions (SNV or SNPs) as well as CNV derived from
LCR rearrangements in the CR1 locus. Also, as CR1 is
presumably involved in Ab clearance from brain,
we investigated whether genetic variation in CR1
affected CSF Ab1 42 levels, as well as levels of T-tau
and P-tau181P. Finally, to replicate our SNP and CNV
findings, we analyzed genetic association in an
independent French cohort.
In an association analysis using 26 SNPs across
the CR1 locus, two SNPs (rs4844610 and rs1408077),
we showed significant association with AD in a
Flanders–Belgian cohort. Both SNPs showed high
pairwise LD (r
2=0.97), and thus recognized the same
association signal. They were also in strong LD
(r
2>0.87), with the two associated SNPs in the French
GWA study, suggesting that they mimic the CR1 GWA
cohort signal. Analysis of rs4844610 in the French
cohort showed a similar, though nonsignificant trend.
A combined cohort analysis provided an OR of 1.31
(95% CI: 1.11–1.55; P=0.0015). Haplotype analysis
identified significant association (OR=1.24 (95% CI:
1.02–1.51; Padj=0.027)) with one haplotype (HapB)
within a 130kb LD-block containing CR1 except for
its first and last exon. In agreement with the French
GWA study,
2 single SNP and haplotype associations
were strongest in APOE e4 carriers. Because CR1 is
potentially involved in clearance of fibrillar Ab
peptides from the brain after complement activation
and opsonization of Ab peptides with C3b frag-
ments,
34 we investigated whether genetic variability
at CR1 could affect CSF Ab1 42 levels in patients. We
calculated a significant association not with the
two AD-associated SNPs (rs4844610, rs1408077), but
with four other SNPs from within the associated
CR1 region (rs646817/rs1746659 and rs11803956/
rs12034383, showing strong pairwise LD). CSF
Ab1 42 levels increased with B20% in carriers homo-
zygous for the rare allele compared with carriers
of the common allele (Figure 3). Seemingly, the
increased CSF Ab1 42 contradicts with the decreased
CSF Ab1 42 levels that are considered indicative of AD
Figure 4 CR1 LCR dosage and CR1 isoform analysis. (a) Dosage analysis of the low-copy repeats (LCRs) underlying CR1
isoforms in selected individuals. Colored dashed lines connect dosage quotient values obtained with multiplex amplicon
quantification (MAQ) amplicons specific for the CR1 LCRs (amplicons 1–3) (Figure 1) referred to by encircled numbers and
three representative reference amplicons. The graph legend shows the isoforms predicted to be encoded by the CR1 copy
number variation (CNV) genotype. The size of the symbols indicates the relative abundance of the respective CNV genotype.
(b) Anti-CR1 immunoblot analysis of selected individuals illustrating the correlation between CNV genotype and protein
isoforms. Lanes are grouped per number of copies of LCR1 present (Table 1).
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with or without mild cognitive impairment.
35 How-
ever, in our study, the increased Ab1 42 levels were
not associated with the risk haplotype HapB but with
haplotypes HapC and HapD. One possible explana-
tion might be that functional variants are located on
HapC and HapD that correspond to the so-called
‘intronic or exonic density polymorphisms’, which
have been correlated with number of CR1 molecules
present on erythrocytes.
4,36 In plasma, C3b mediates
adherence of Ab peptides to erythrocyte CR1, a
process, which is impaired early in the disease.
18
However, it is doubtful that these variants can explain
the observed association as genotype analysis of
rs3811831, a SNP in high LD with the erythrocyte
density polymorphisms, was not associated with AD
or with CSF Ab levels (data not shown). Additional
studies of CR1 association and CSF Ab1 42 levels in
AD will be needed to analyze a potential influence of
CR1 genetic variability.
Using a MAQ dosage assay, we were able to show
that the LCR variability in the CR1 locus was driven
nearly exclusively by variability of the coding LCR1
in CR1. Association analysis of LCR1 copy number
with AD indicated that individuals carrying an extra
LCR1 copy had B30% increased risk (Padj=0.028,
OR=1.32 (95% CI: 1.03–1.69)). Presence of an extra
copy of LCR1 (i.e., LCR10) defines CR1-S (allelic
frequency 15%) that carries an extra set of C3b/C4b
binding sites compared with the more frequent
shorter CR1-F (allelic frequency 83%) (Figure 1).
Further, we showed that the LCR1 CNV was in high
LD with SNPs rs4844610 and rs1408077 (r
2X0.76),
indicating that the association with CR1 can be
explained by the intragenic CNV underlying CR1-S
and CR1-F and, thus, number of C3b/C4b binding
sites in CR1. Moreover, the observation that analysis
of rs4844610 in the replication sample only showed
a trend toward association, whereas the LCR1 CNV
showed significant association in both study popu-
lations, independently, further strengthens the
hypothesis that the CR1 CNV likely explains the asso-
ciation initially observed in the GWAS. It should
be noted, however, that our MAQ dosage assay
could not distinguish among carriers of four LCR1
copies those homozygous for CR1-S or heterozygous
CR1-D/CR1-F. Also, our analysis did not include
LCR2 variability (e.g., CR1-F0). However, in accor-
dance with the reported frequencies, the respective
isoforms are rare (1.7–1.8%) in our cohort, therefore
unlikely to have wrongly affected the observed CR1
CNV association.
How the CR1 CNV genetic variations affect the
biological processes that eventually culminate into
AD remains unclear. One explanation could be that
the longer CR1-S, with its additional C3b binding
site (Figure 1), increases Ab clearance from brain
either through attacking Ab plaques directly or by
functioning as an Ab-sink in the periphery, mediated
by erythrocyte CR1. The observed association with
AD with CR1-S, however, contradicts this hypothesis.
Further, we did not observe an association between
CR1-S and CSF Ab1 42, although we cannot exclude
that the lack of association results from the use of
levels of soluble Ab1 42,
35 whereas CR1-S perhaps
only affects aggregated Ab1 42.
16,17 Nevertheless,
we did obtain evidence of association between other
genetic CR1 variants and CSF Ab1 42, indicating
CR1 may have a role in AD pathogenesis through an
effect on Ab. Another explanation for the association
with CR1-S might lie in the enhancement of
the proteins’ inhibitory potential (cofactor activity)
towards complement activation, through its gained
C3b site (Figure 1). One of the functions of CR1
is controlling amplification of the complement
cascade. By binding to C3b-opsonized particles, CR1
will function as cofactor of Factor I, which converts
C3b into its inactivated form C3b. The latter is unable
to sustain or amplify the complement cascade,
ultimately dampening the immune response and
minimizing bystander tissue damage.
37 Therefore,
CR1-S might represent a more potent inhibitor of
complement cascade amplification than CR1-F,
resulting in a shorter-lasting complement reaction
and reducing the levels of C3b fragments that can
opsonize Ab aggregates. Thus, individuals carrying
one or two CR1-S alleles might exhibit an elevated
inhibition of a potentially neuroprotective process
(e.g., clearance of Ab aggregates from the brain),
which is in agreement with several observations
in AD mouse models, in which inhibition of
complement activation was shown to correlate with
enhanced Ab plaque deposition and loss of neuronal
integrity.
34,38 On the other hand, complement acti-
vation can elicit a potent immune reaction in the
brain, which might kill healthy bystander neurons
in the process. In this light, inhibition of comple-
ment activation could have a more beneficial out-
come, as was likewise observed in AD mouse models
in which the classical complement cascade was
inhibited.
19,20 However, the fact that the longer
CR1-S with more binding sites that can inhibit
complement activation through enhanced cofactor
activity, increases risk for developing AD argues
against this idea.
In summary, our data strongly support a role for
CR1 in the pathogenesis of AD. We were able to
replicate the genetic association with AD risk and
extended the genetic findings by fine mapping the
SNP association to a 130kb genomic region compris-
ing mostly of CR1. Further, we showed that the
association might likely be explained by an intragenic
CNV that translates into the two major CR1 isoforms
differing in number of C3b/C4b and cofactor activity
sites, and thus different functional roles in the
complement cascade. Lastly, we were able to replicate
our genetic findings in an additional French cohort,
further implying that an extra LCR1 because of
duplication at the intragenic CR1 CNV increases risk
for AD. However, how exactly these genetic and
biological findings contribute to AD pathogenesis
remains to be determined.
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